Constitutively active ErbB2 regulates cisplatin-induced cell death in breast cancer cells via pro- and antiapoptotic mechanisms

Molecular Cancer Research

Volumn 13, Issue 1, 2015, Pages 63-77

  Sigurosson, Haraldur H ^a   Olesen, Christina W ^a   Dybboe, Rie ^a   Lauritzen, Gitte ^a   Pedersen, Stine F ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CASPASE 7; CASPASE 9; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FODRIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BCL 2; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; SODIUM PROTON EXCHANGE PROTEIN 1; BICARBONATE SODIUM COTRANSPORTER; CATION TRANSPORT PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; ERBB2 PROTEIN, HUMAN; SLC4A7 PROTEIN, HUMAN; SLC9A1 PROTEIN, HUMAN; SODIUM PROTON EXCHANGE PROTEIN;

APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; MCF 7 CELL LINE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; BIOSYNTHESIS; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

APOPTOSIS; BREAST NEOPLASMS; CATION TRANSPORT PROTEINS; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; PHOSPHORYLATION; RECEPTOR, ERBB-2; SODIUM-BICARBONATE SYMPORTERS; SODIUM-HYDROGEN ANTIPORTER;

EID: 84921794851     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0011     Document Type: Article

References (54)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
2. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007;99:628-38.
3. Saez R, Molina MA, Ramsey EE, Rojo F, Keenan EJ, Albanell J, et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006;12:424-31.
4. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006;3:269-80.
5. De Keulenaer GW, Doggen K, Lemmens K. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res 2010;106:35-46.
6. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829-38.
7. Decatris MP, Sundar S, O'Byrne KJ. Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev 2004;30:53-81.
8. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7:573-84.
9. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79.
10. Basu A, Krishnamurthy S. Cellular responses to Cisplatin-induced DNA damage. J Nucleic Acids 2010;2010.pii.201367.
11. Dimanche-Boitrel MT, Meurette O, Rebillard A, Lacour S. Role of early plasmamembrane events in chemotherapy-induced cell death. Drug Resist Updat 2005;8:5-14.
12. Rebillard A, Tekpli X, Meurette O, Sergent O, LeMoigne-Muller G, Vernhet L, et al. Cisplatin-induced apoptosis involves membrane fluidification via inhibition of NHE1 in human colon cancer cells. Cancer Res 2007;67:7865-74.
13. Abbas T, Dutta A. p21 in cancer: intricate networks andmultiple activities. Nat Rev Cancer 2009;9:400-14.
14. Haupt S, Berger M,Goldberg Z, Haupt Y. Apoptosis - the p53 network. J Cell Sci 2003;116:4077-85.
15. Harris LN, Yang L, Tang C, Yang D, Lupu R. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2. Clin Cancer Res 1998;4:1005-12.
16. Egeblad M, Jaattela M. Cell death induced by TNF or serum starvation is independent of ErbB receptor signaling in MCF-7 breast carcinoma cells. Int J Cancer 2000;86:617-25.
17. Angelini PD, Zacarias Fluck MF, Pedersen K, Parra-Palau JL, Guiu M, Bernado MC, et al. Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence. Cancer Res 2013;73:450-8.
18. Lauritzen G, Jensen MB, Boedtkjer E, Dybboe R, Aalkjaer C, Nylandsted J, et al. NBCn1 and NHE1 expression and activity in DeltaNErbB2 receptor-expressing MCF-7 breast cancer cells: contributions to pHi regulation and chemotherapy resistance. Exp Cell Res 2010;316:2538-53.
19. Sigurdsson H, Olesen CW, Dybboe R, Lauritzen G, Pedersen SF. Cisplatin-induced cell death in MCF-7 breast cancer cells: Roles of (Delta) NErbB2 and pH regulatory ion transporters NHE1 and NBCn1. FASEB J 27, 727.5 2013.
20. Damkier HH, Nielsen S, Praetorius J. An anti-NH2-terminal antibody localizes NBCn1 to heart endothelia and skeletal and vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2006;290:H172-80.
21. Schneider L, Stock CM, Dieterich P, Jensen BH, Pedersen LB, Satir P, et al. The Na+/H +exchanger NHE1 is required for directional migration stimulated via PDGFR-alpha in the primary cilium. J Cell Biol 2009;185:163-76.
22. Rasmussen M, Alexander RT, Darborg BV, Mobjerg N, Hoffmann EK, Kapus A, et al. Osmotic cell shrinkage activates ezrin/radixin/moesin (ERM) proteins: activation mechanisms and physiological implications. Am J Physiol Cell Physiol 2008;294:C197-212.
23. Nylandsted J, Jaattela M, Hoffmann EK, Pedersen SF. Heat shock protein 70 inhibits shrinkage-induced programmed cell death via mechanisms independent of effects on cell volume-regulatory membrane transport proteins. Pflugers Arch 2004;449:175-85.
24. Janicke RU. MCF-7 breast carcinoma cells do not express caspase-3. Breast Cancer Res Treat 2009;117:219-21.
25. Janicke RU, Ng P, Sprengart ML, Porter AG. Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis. J Biol Chem 1998;273:15540-5.
26. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 2007;282:24131-45.
27. Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005;5:726-34.
28. Roos WP, Kaina B. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett 2013;332:237-48.
29. Huang S, Chen M, Shen Y, Shen W, Guo H, Gao Q, et al. Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer Lett 2012;315:198-205.
30. Han Z, Feng J, Hong Z, Chen L, Li W, Liao S, et al. Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells. Biochem Biophys Res Commun 2013;435:188-94.
31. Hawthorne VS, Huang WC, Neal CL, Tseng LM, Hung MC, Yu D. ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells. Mol Cancer Res 2009;7:592-600.
32. Gorbatenko A, Olesen CW, Morup N, Thiel G, Kallunki T, Valen E, et al. ErbB2 upregulates the Na+,HCO3--cotransporter NBCn1/SLC4A7 in human breast cancer cells via Akt, ERK, Src, and Kruppel-like factor 4. FASEB J 2014;28:350-63.
33. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9:47-59.
34. Boedtkjer E, Bunch L, Pedersen SF. Physiology, Pharmacology and Pathophysiology of the pH Regulatory Transport Proteins NHE1 and NBCn1: Similarities, Differences, and Implications for Cancer Therapy. Curr Pharm Des 2012;18:1345-71.
35. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012;31:1869-83.
36. Devarajan E, Sahin AA, Chen JS, Krishnamurthy RR, Aggarwal N, Brun AM, et al. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene 2002;21:8843-51.
37. Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998;273:9357-60.
38. Janicke RU. MCF-7 breast carcinoma cells do not express caspase-3. Breast Cancer Res Treat 2009;117:219-21.
39. Henkels KM, Turchi JJ. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res 1999;59:3077-83.
40. Yang C, Kaushal V, Haun RS, Seth R, Shah SV, Kaushal GP. Transcriptional activation of caspase-6 and -7 genes by cisplatin-induced p53 and its functional significance in cisplatin nephrotoxicity. Cell Death Differ 2008;15:530-44.
41. Fehrenbacher N, Bastholm L, Kirkegaard-Sorensen T, Rafn B, Bottzauw T, Nielsen C, et al. Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosome-associated membrane proteins 1 and 2. Cancer Res 2008;68:6623-33.
42. Claerhout S, Verschooten L, Van KS, De VR, Proby C, Agostinis P, et al. Concomitant inhibition of AKT and autophagy is required for efficient cisplatin-induced apoptosis of metastatic skin carcinoma. Int J Cancer 2010;127:2790-803.
43. Saeki K, Yuo A, Okuma E, Yazaki Y, Susin SA, Kroemer G, et al. Bcl-2 down-regulation causes autophagy in a caspase-independent manner in human leukemic HL60 cells. Cell Death Differ 2000;7:1263-9.
44. Qin JZ, Stennett L, Bacon P, Bodner B, Hendrix MJ, Seftor RE, et al. p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol Cancer Ther 2004;3:895-902.
45. Jullig M, Zhang WV, Ferreira A, Stott NS. MG132 induced apoptosis is associated with p53-independent induction of pro-apoptotic Noxa and transcriptional activity of beta-catenin. Apoptosis 2006;11:627-41.
46. Le XF, Marcelli M, McWatters A, Nan B, Mills GB, O'Brian CA, et al. Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity. Oncogene 2001;20:8258-69.
47. Kumar R, Mandal M, Lipton A, Harvey H, Thompson CB. Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin Cancer Res 1996;2:1215-9.
48. Menendez JA, Mehmi I, Lupu R. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage. Int J Oncol 2005;26:649-59.
49. Rich IN, Worthington-White D, Garden OA, Musk P. Apoptosis of leukemic cells accompanies reduction in intracellular pH after targeted inhibition of the Na(+)/H(+) exchanger. Blood 2000;95:1427-34.
50. Schelling JR, bu Jawdeh BG. Regulation of cell survival by Na+/H+ exchanger-1 (NHE1). Am J Physiol Renal Physiol 2008;295:F625-32.
51. Pedersen SF, Lauritzen G, Andersen AD. The Na+/H+ exchanger NHE1: diverse roles in regulation of cellular signaling pathways controlling proliferation, motility, and survival. In: Proton homeostasis in tumorigenesis and cell death processes. Research Signpost. Ed. D Lagadic-Gossmann, pp. 13-28.
52. Wang ZQ, Stingl L, Morrison C, Jantsch M, Los M, Schulze-Osthoff K, et al. PARP is important for genomic stability but dispensable in apoptosis. Genes Dev 1997;11:2347-58.
53. Leist M, Single B, Kunstle G, Volbracht C, Hentze H, Nicotera P. Apoptosis in the absence of poly-(ADP-ribose) polymerase. Biochem Biophys Res Commun 1997;233:518-22.
54. Zhao R, Oxley D, Smith TS, Follows GA, Green AR, Alexander DR. DNA damage-induced Bcl-xL deamidation is mediated by NHE-1 antiport regulated intracellular pH. PLoS Biol 2007;5:e1.